Stem cells emerge as leading stock

Published: 2009-03-12 07:00:00

Updated: 2009-03-12 07:00:00

Stem cell-related stocks have come back to the throne as the U.S. President Barack Obama will sign an executive order overturning President’s Bush’s embryonic stem cell research policy, according to Mirae Asset

Stocks of Samjin Pharm and Cho-A Pharm have recorded 11.15 percent and 14.90 percen...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK